HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$4.74 USD
+0.02 (0.42%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
HOOKIPA Pharma Inc. [HOOK]
Reports for Purchase
Showing records 21 - 38 ( 38 total )
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Immunogenicity Data at AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
HB-201 Delivers Proof of Concept for HPV16+ Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
CMV Vaccine?s Clinical Benefit Validated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
CMV Vaccine Efficacy Data Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Update; Counting Down to HB-101 and -201 Readouts
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Preliminary CMV-Specific T-Cell Responses Surpass Our Threshold for Expected Efficacy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Heterologous E6/E7 Vaccine Now in the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
The Pandemic May Whittle the Data, but not the Timing
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
VaxWave and TheraT Chugging Along to Anticipated Data Readouts in Line With Prior Guidance
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Runners up Is the New Killing It, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
mRNA vs. Arenavirus, Albeit in Different CMV Settings, Would Make for an Interesting Contrast
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; Setup for Platform Validation During 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
We initiate with a Buy rating and a 12-month price target of $15/share.
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D